Esomeprazole
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease (GERD)
Conditions
Gastroesophageal Reflux Disease (GERD)
Trial Timeline
Nov 1, 2003 → Oct 1, 2007
NCT ID
NCT00574925About Esomeprazole
Esomeprazole is a approved stage product being developed by AstraZeneca for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00574925. Target conditions include Gastroesophageal Reflux Disease (GERD).
What happened to similar drugs?
17 of 20 similar drugs in Gastroesophageal Reflux Disease (GERD) were approved
Approved (17) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01370538 | Phase 3 | Completed |
| NCT01370525 | Phase 3 | Completed |
| NCT00474019 | Phase 1 | Completed |
| NCT00427635 | Phase 3 | Completed |
| NCT00384592 | Approved | Completed |
| NCT00318968 | Approved | Completed |
| NCT00608712 | Approved | Completed |
| NCT00251979 | Phase 3 | Completed |
| NCT00392002 | Approved | Completed |
| NCT00242736 | Approved | Completed |
| NCT00291746 | Approved | Completed |
| NCT00206440 | Phase 3 | Terminated |
| NCT00243724 | Phase 3 | Completed |
| NCT00524251 | Pre-clinical | Completed |
| NCT00251966 | Phase 3 | Completed |
| NCT00251901 | Phase 3 | Completed |
| NCT00120315 | Approved | Completed |
| NCT00574925 | Approved | Completed |
| NCT00222131 | Phase 2 | Completed |
| NCT00318084 | Approved | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease (GERD)